Shares of Fortrea Holdings Inc. (FTRE) surged 10.8% in pre-market trading on November 8, 2024, after the contract research organization (CRO) reported solid third-quarter results and increased its revenue guidance for the full year.
For the quarter ended September 30, 2024, Fortrea posted revenue of $674.9 million, down slightly from the prior year but in line with expectations. While the company reported a GAAP net loss of $18.5 million, its adjusted EBITDA came in at $64.2 million, indicating underlying profitability.
The highlight of Fortrea's Q3 performance was its robust backlog growth and book-to-bill ratio. The company's backlog grew to $7.57 billion, and its book-to-bill ratio stood at an impressive 1.23x, reflecting strong demand for its clinical trial services. This bodes well for future revenue growth, as the company executes on this backlog.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。